MREO

Mereo BioPharma

3.81 USD
+0.42
12.39%
At close Dec 24, 4:00 PM EST
After hours
3.74
-0.07
1.84%
1 day
12.39%
5 days
12.06%
1 month
12.72%
3 months
-5.93%
6 months
1.33%
Year to date
65.65%
1 year
64.94%
5 years
246.36%
10 years
-41.38%
 

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 33

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]

41% more call options, than puts

Call options by funds: $3.18M | Put options by funds: $2.26M

20% more capital invested

Capital invested by funds: $363M [Q2] → $435M (+$71.9M) [Q3]

0.61% less ownership

Funds ownership: 14.36% [Q2] → 13.75% (-0.61%) [Q3]

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

3% less funds holding

Funds holding: 79 [Q2] → 77 (-2) [Q3]

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
84%
upside
Avg. target
$7.75
103%
upside
High target
$10
162%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
LifeSci Capital
Cory Jubinville
100% 1-year accuracy
1 / 1 met price target
162%upside
$10
Outperform
Initiated
24 Dec 2024
Jefferies
Maury Raycroft
0% 1-year accuracy
0 / 10 met price target
84%upside
$7
Buy
Initiated
6 Dec 2024
Needham
Gil Blum
18% 1-year accuracy
29 / 164 met price target
84%upside
$7
Buy
Reiterated
12 Nov 2024
Cantor Fitzgerald
Kristen Kluska
38% 1-year accuracy
40 / 105 met price target
84%upside
$7
Overweight
Reiterated
1 Oct 2024

Financial journalist opinion

Positive
Seeking Alpha
4 weeks ago
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a partner for Alvelestat's phase 3 trial, potentially boosting stock value.
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
Neutral
GlobeNewsWire
1 month ago
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT.
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the Company believes will provide runway into 2027, through multiple key inflection points.
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
3 months ago
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST.
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
Neutral
GlobeNewsWire
4 months ago
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $87.4 million as of June 30, 2024, which includes the net proceeds of the Company's $50 million registered direct offering in June 2024.
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
6 months ago
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate purposes. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions.
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Neutral
GlobeNewsWire
6 months ago
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST.
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Neutral
GlobeNewsWire
7 months ago
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026.
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Negative
Zacks Investment Research
8 months ago
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Neutral
GlobeNewsWire
8 months ago
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST.
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Charts implemented using Lightweight Charts™